1-3 of 3
Terra Lasho
Close
Sort by
Journal Articles

The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance

Marissa Li, Anmol Baranwal, Mark Gurney, Syed N. Shah, Aref Al-Kali, Hassan Alkhateeb, James Foran, Cecilia Arana Yi, Laura Ongie, Dong Chen, Abhishek Mangaonkar, Kristen McCullough, Ayalew Tefferi, Terra Lasho, Christy Finke, Mrinal M. Patnaik, Mithun Vinod Shah
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3130–3139.
https://doi.org/10.1182/bloodadvances.2023012357
Published: 2024
Includes: Supplemental data
Journal Articles

Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients

Clinical Trials & Observations
Marissa Li, Moritz Binder, Terra Lasho, Alejandro Ferrer, Naseema Gangat, Aref Al-Kali, Abhishek Mangaonkar, Michelle Elliott, Mark Litzow, William Hogan, Animesh Pardanani, Alexandra Wolanskyj-Spinner, Matthew Howard, Rebecca L. King, Mithun Shah, Hassan Alkhateeb, Kebede Begna, Ayalew Tefferi, Christy Finke, Jennifer Oliveira, Rhett Ketterling, Horatiu Olteanu, Mrinal M. Patnaik
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2272–2278.
https://doi.org/10.1182/bloodadvances.2020003976
Published: 2021
Includes: Supplemental data
Journal Articles

SF3B1 -mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia–free survival

Clinical Trials & Observations
Kitsada Wudhikarn, Sanam Loghavi, Abhishek A. Mangaonkar, Aref Al-Kali, Moritz Binder, Ryan Carr, Kaaren Reichard, Christy Finke, Matthew Howard, Naseema Gangat, Ayalew Tefferi, Rami Komrokji, Najla Ali, Terra Lasho, Rhett Ketterling, Eric Padron, Mrinal M. Patnaik
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5716–5721.
https://doi.org/10.1182/bloodadvances.2020003345
Published: 2020
Includes: Supplemental data